<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790855</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0634</org_study_id>
    <nct_id>NCT00790855</nct_id>
  </id_info>
  <brief_title>Bendamustine in Acute Leukemia and MDS</brief_title>
  <official_title>Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High-Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the Phase I part of this clinical research study is to find the highest safe dose&#xD;
      of bendamustine that can be given to patients with acute myelogenous leukemia (AML), Acute&#xD;
      lymphoblastic leukemia (ALL), Chronic myelogenous (or myeloid) leukemia (CML) in blastic&#xD;
      phase, Chronic Myelomonocytic Leukemia (CMML), and myelodysplastic syndromes (MDS).&#xD;
&#xD;
      The goal of the Phase II part of this clinical research study is to learn if bendamustine can&#xD;
      help to control AML, ALL and MDS. The safety of this drug will continue to be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drug:&#xD;
&#xD;
      Bendamustine is designed to damage and destroy the DNA of cancer cells.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to a study&#xD;
      group based on when you joined this study. Up to 60 participants will be enrolled in the&#xD;
      Phase I portion of the study, and up to 3 groups of 31 participants will be enrolled in Phase&#xD;
      II.&#xD;
&#xD;
      If you are enrolled in the Phase I portion, the dose of bendamustine you receive will depend&#xD;
      on when you joined this study. The first group of participants will receive the lowest dose&#xD;
      level of bendamustine. Each new group will receive a higher dose of bendamustine than the&#xD;
      group before it, if no intolerable side effects were seen. This will continue until the&#xD;
      highest tolerable dose of bendamustine is found.&#xD;
&#xD;
      If you are enrolled in the Phase II portion, you will receive bendamustine at the highest&#xD;
      dose that was tolerated in the Phase I portion.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will receive bendamustine through a needle or catheter in your vein over 2 hours twice on&#xD;
      Days 1-4 of every 4 week study cycle. You will begin a new study cycle when your blood cell&#xD;
      counts have returned to an appropriate level. You may begin a new study cycle earlier if your&#xD;
      disease gets worse or does not improve.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      Blood (about 2 tablespoons) will be drawn for routine tests every 3-7 days during Cycle 1,&#xD;
      and then every 1-2 weeks during all other cycles.&#xD;
&#xD;
      A bone marrow aspirate will be performed to check the status of the disease after Cycle 1 and&#xD;
      every 3-4 Cycles thereafter, or as needed to document response.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may remain on study for as long as you are benefitting. You will be taken off study early&#xD;
      if the disease gets worse or intolerable side effects occur.&#xD;
&#xD;
      This is an investigational study. Bendamustine is not FDA approved or commercially available&#xD;
      in the United States. At this time, bendamustine is only being used in research.&#xD;
&#xD;
      Up to 153 patients will take part in this study. All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of Response&#xD;
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>During course 1 (4 week cycle)</time_frame>
    <description>The MTD is the highest dose level in which &lt;2 patients of 6 develop first cycle dose limiting toxicity (DLT). MTD assessed during course 1 (4 week cycle), every 3-7 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Response</measure>
    <time_frame>1 - 24 week cycles (up to 8 weeks)</time_frame>
    <description>A complete response (CR) is defined as normalization of the bone marrow and peripheral blood counts with &lt;/= 5% marrow blasts in a normo-or hypercellular marrow, with a granulocyte count of &gt;/= 10^9/L and a platelet count of &gt;/=100 X 10^9/L. A partial response (PR) was defined as for CR, but with only &gt;/=50% reduction of marrow blasts and to a range of 6%-25%. A marrow complete response was defined as a reduction of marrow blasts to &lt;/=5% but without recovery of peripheral counts.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Bendamustine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose 50 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Starting dose of 50 mg/m^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.</description>
    <arm_group_label>Bendamustine</arm_group_label>
    <other_name>TreandaÂ®</other_name>
    <other_name>Bendamustine Hydrochloride</other_name>
    <other_name>Bendamustine HCI</other_name>
    <other_name>CEP-18083</other_name>
    <other_name>SDX-105</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients will be 16 years of age or older.&#xD;
&#xD;
          2. Patients must have relapsed/refractory leukemias for which no standard therapies are&#xD;
             anticipated to result in a durable remission (longer than 3 months). Patients with&#xD;
             poor-risk myelodysplasia (MDS) [i.e. refractory anemia with excess blasts (RAEB-1 or&#xD;
             RAEB-2) by World Health Organization (WHO) classification] and chronic myelomonocytic&#xD;
             leukemia (CMML) are also candidates for this protocol. Relapsed/refractory leukemias&#xD;
             include acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic&#xD;
             myelogenous leukemia (CML) in blastic phase.&#xD;
&#xD;
          3. Continued from #2: Elderly patients with AML who are not eligible for frontline&#xD;
             standard therapy, or who refuse to be treated with intensive chemotherapy, may be&#xD;
             eligible. The phase II portion of the study will enroll patients with AML, MDS, and&#xD;
             ALL. Patients with CML and CMML will not participate in the phase II portion of the&#xD;
             study. Patients who are being considered for stem cell transplant are also eligible&#xD;
             for this protocol.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.&#xD;
&#xD;
          5. Women of child-bearing potential (i.e., woman has not been naturally postmenopausal&#xD;
             for at least 24 consecutive months or not surgically sterile) must use acceptable&#xD;
             contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or&#xD;
             double barrier device), and must have a negative serum or urine pregnancy test within&#xD;
             2 weeks prior to beginning treatment on this trial. Sexually active men must also use&#xD;
             acceptable contraceptive methods for the duration of time on study. Men and women must&#xD;
             maintain effective contraception until 4 weeks after the last dose of drug is&#xD;
             administered.&#xD;
&#xD;
          6. Must be able and willing to give written informed consent.&#xD;
&#xD;
          7. In the absence of rapidly progressing disease, the interval from prior treatment to&#xD;
             time of study drug administration should be at least 2 weeks for cytotoxic agents, or&#xD;
             at least 5 half-lives for noncytotoxic agents. If the patient is on hydroxyurea to&#xD;
             control peripheral blood leukemic cell counts, the patient must be off hydroxyurea for&#xD;
             at least 24 hours before initiation of treatment on this protocol. Persistent&#xD;
             clinically significant toxicities (any grade 2 or worse toxicities, non-hematologic or&#xD;
             hematologic) from prior chemotherapy must not be greater than Grade 1.&#xD;
&#xD;
          8. Patients must have the following clinical laboratory values unless considered due to&#xD;
             leukemic organ involvement: 1) Serum creatinine &lt;/= 2.0 mg/dl; 2) Total bilirubin &lt;/=&#xD;
             1.5 times the upper limit of normal unless considered due to Gilbert's syndrome; 3)&#xD;
             Alanine aminotransferase (ALT), or aspartate aminotransferase (AST) &lt;/= 3 times the&#xD;
             upper limit of normal unless considered due to organ leukemic involvement.&#xD;
&#xD;
          9. Patients with active Central Nervous System (CNS) disease are included and will be&#xD;
             treated concurrently with intrathecal therapy.&#xD;
&#xD;
         10. Phase II Portion: All above criteria apply. After the phase I portion, patients&#xD;
             eligibility will be for only 3 disease categories which will accrue in parallel: 1)&#xD;
             AML, 2) MDS, and 3) ALL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled intercurrent illness including, but not limited to uncontrolled infection&#xD;
             (i.e. persistent fever, clinical deterioration), acute congestive heart failure and&#xD;
             exacerbation, cardiac arrhythmia, chronic liver disease, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirements.&#xD;
&#xD;
          2. Active heart disease including myocardial infarction within previous 3 months,&#xD;
             unstable angina, arrhythmias not controlled by medication, or uncontrolled congestive&#xD;
             heart failure. Patients with New York Heart Association (NYHA) class 3 or 4 are&#xD;
             excluded.&#xD;
&#xD;
          3. Patients receiving any other standard or investigational treatment for their&#xD;
             hematologic malignancy, except as permitted under Inclusion #9 above.&#xD;
&#xD;
          4. Pregnant or breast feeding females are excluded because the effects of bendamustine on&#xD;
             a fetus or nursing child are unknown.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop M. Kantarjian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>November 13, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <results_first_submitted>June 22, 2012</results_first_submitted>
  <results_first_submitted_qc>September 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2012</results_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bendamustine</keyword>
  <keyword>Acute Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>MDS</keyword>
  <keyword>ALL</keyword>
  <keyword>AML</keyword>
  <keyword>CML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Details: 11/6/2008 to 9/1/2010. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Out of 27 participants registered, two were found ineligible and did not participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bendamustine</title>
          <description>Starting dose 50 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bendamustine</title>
          <description>Starting dose 50 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="22" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>The MTD is the highest dose level in which &lt;2 patients of 6 develop first cycle dose limiting toxicity (DLT). MTD assessed during course 1 (4 week cycle), every 3-7 days.</description>
        <time_frame>During course 1 (4 week cycle)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine</title>
            <description>Starting dose 50 mg/m^2 intravenously, over 2 hours twice on Days 1-4 of every 4 week study cycle, with dose escalation of 25 mg/m^2 for 3 levels.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>The MTD is the highest dose level in which &lt;2 patients of 6 develop first cycle dose limiting toxicity (DLT). MTD assessed during course 1 (4 week cycle), every 3-7 days.</description>
          <units>mg/m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Response</title>
        <description>A complete response (CR) is defined as normalization of the bone marrow and peripheral blood counts with &lt;/= 5% marrow blasts in a normo-or hypercellular marrow, with a granulocyte count of &gt;/= 10^9/L and a platelet count of &gt;/=100 X 10^9/L. A partial response (PR) was defined as for CR, but with only &gt;/=50% reduction of marrow blasts and to a range of 6%-25%. A marrow complete response was defined as a reduction of marrow blasts to &lt;/=5% but without recovery of peripheral counts.</description>
        <time_frame>1 - 24 week cycles (up to 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bendamustine (75 mg/m^2)</title>
            <description>75 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Response</title>
          <description>A complete response (CR) is defined as normalization of the bone marrow and peripheral blood counts with &lt;/= 5% marrow blasts in a normo-or hypercellular marrow, with a granulocyte count of &gt;/= 10^9/L and a platelet count of &gt;/=100 X 10^9/L. A partial response (PR) was defined as for CR, but with only &gt;/=50% reduction of marrow blasts and to a range of 6%-25%. A marrow complete response was defined as a reduction of marrow blasts to &lt;/=5% but without recovery of peripheral counts.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marrow Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bendamustine</title>
          <description>Starting dose 50 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Liver function abnormality</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hagop M. Kantarjian, M.D.</name_or_title>
      <organization>The University of MD Anderson Cancer Center</organization>
      <phone>713-792-7026</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

